LINGEVIA™ THC-HS ORAL DROPS – ADJUNCT CANCER THERAPY

LINGEVIA™ THC-HS Advanced treatment Oral Drops

Precision Cannabinoid Science | Advanced Oral & Sublingual Delivery

LINGEVIA™ THC-HS Oral Drops represent an advanced cannabinoid formulation concept developed around highly concentrated THC-hemisuccinate (THC-HS), a chemically modified form of delta-9-tetrahydrocannabinol investigated for its potential as a cannabinoid delivery prodrug.

Produced as a 93%+ THC-HS concentrate, complemented by a carefully selected spectrum of CBD, CBG, CBN and CBC, LINGEVIA is designed for further pharmaceutical formulation development and evaluation of oral and sublingual administration.

The formulation is intended for adult patients experiencing complex symptom-management needs, including those associated with advanced illness and oncology supportive care. Its clinical effectiveness, safety, and suitability for such patients have not yet been established.

Innovative Oral Delivery Process

LINGEVIA’s formulation incorporates a specialized cannabinoid delivery matrix designed for advanced cannabinoid solubility, formulation stability, accurate dispensing and potential absorption through the oral mucosa.

• Advanced Prodrug Technology: THC-HS incorporates a hemisuccinate modification intended to alter physicochemical properties compared with conventional THC.
• Potential Oromucosal Absorption: Sublingual administration offers an opportunity for absorption through tissues beneath the tongue. The extent of direct mucosal absorption of THC-HS remains to be established.
• Dual Absorption Pathways: Depending on formulation and administration, cannabinoids may enter circulation through oral mucosal absorption or through the gastrointestinal tract after swallowing.
• Precision Dispensing: A calibrated dropper can support consistent measurement of liquid volume, along with validated cannabinoid concentrations and uniformity.
• Duration of Action: Conventional oral cannabis formulations can produce effective relief lasting several hours. LINGEVIA’s specific onset, duration and pharmacokinetic profile require ongoing clinical evaluation.

Clinical Research Positioning

LINGEVIA is developed as a supportive adjunct treatment option for the following areas of clinical interest:

• Persistent and severe symptom burdens associated with advanced illness
• Cancer-related discomfort and supportive palliative care
• Chemotherapy-associated nausea and appetite disturbances
• Sleep disruption accompanying chronic disease
• Neurological symptom management, including spasticity

Why THC-HS Matters

Conventional cannabis oils typically deliver cannabinoids in their familiar chemical forms. THC-HS introduces a different formulation strategy through chemical modification of the THC molecule.

The scientific distinctions include:

• Modified Molecular Structure: The hemisuccinate group allow formulation properties that differ from unmodified THC.
• Prodrug Potential: THC-HS has been investigated as a compound capable of releasing THC following conversion in the body.
• Formulation Development: Researchers have evaluated THC-HS for solubility, stability, membrane transport and drug-release characteristics.

Differentiation in the Market

LINGEVIA is positioned as a research-led oral cannabinoid delivery option rather than a conventional recreational cannabis oil.

Its distinguishing characteristics include:

• THC-HS-based formulation research
• Combined cannabinoid spectrum incorporating THC-HS, CBD, CBG, CBN and CBC
• Compact oral-drop delivery format
• Potential sublingual administration
• Development emphasis on validated concentration, stability and dose uniforming

Responsible Product Statement

LINGEVIA™ THC-HS Oral Drops are a cannabinoid formulation. its safety, pharmacokinetics, oral bioavailability, tolerability and clinical effectiveness have not been established through product-specific human clinical trials yet. Preclinical research has examined the biological effects of THC and other cannabinoids in experimental cancer models. Such findings do not establish that THC-HS oral drops, inhibit tumour progression, outcomes in humans.

LINGEVIA is not an established cancer treatment and should not replace chemotherapy, radiation therapy, immunotherapy, surgery, prescribed symptom-management medication or professional oncology care.

Any future clinical application should take place within an appropriate regulatory and medical framework, with particular attention to psychoactive effects, medication interactions, formulation safety and individual patient vulnerability.